1 – 12 of 12
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2009
-
Mark
Validation of the predictive value of tissue inhibitor of metalloproteinases-1 for the response to first-line chemotherapy in metastatic breast cancer.
(
- Contribution to journal › Published meeting abstract
-
Mark
TIMP-1 and responsiveness of estrogen receptor negative breast cancer to preoperative epirubicin and cyclophosphamide with or without gefitinib
(
- Contribution to journal › Published meeting abstract
- 2006
-
Mark
Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum
(
- Contribution to journal › Article
- 2005
-
Mark
Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic marker in rectal cancer patients. An EORTC-receptor and Biomarker Group collaboration
(
- Contribution to journal › Article
- 2004
-
Mark
Association between preoperative plasma levels of tissue inhibitor of metalloproteinases 1 and rectal cancer patient survival: a validation study
(
- Contribution to journal › Article
- 2003
-
Mark
Pooled analysis of prognostic impact of uPA and PAI-I in breast cancer patients
(
- Contribution to journal › Article
- 2002
-
Mark
Measurement of the noncomplexed free fraction of tissue inhibitor of metalloproteinases I in plasma by immunoassay
(
- Contribution to journal › Article
-
Mark
Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer
(
- Contribution to journal › Article
-
Mark
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 8377 breast cancer patients
(
- Contribution to journal › Article
- 2001
-
Mark
S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer
(
- Contribution to journal › Article
-
Mark
Urokinase plasminogen activator and its inhibitor, PAI-1, in association with progression-free survival in early stage endometrial cancer
(
- Contribution to journal › Article
-
Mark
Prognostic importance of the soluble plasminogen activator receptor, suPAR, in plasma from rectal cancer patients
(
- Contribution to journal › Article